Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1576
Star Bulk Carriers
SBLK
$3.24B
| $6.13M | 0.01% |
623,080
+46,481
| +8% | +$432K |
|
1577
Radian Group
RDN
$4.98B
| $6.12M | 0.01% |
374,300
-108,700
| -23% | -$1.86M |
|
1578
Sierra Bancorp
BSRR
$532M
| $6.11M | 0.01% |
248,800
+34,200
| +16% | +$870K |
|
|
CEMP
1579
DELISTED
Cempra, Inc.
CEMP
| $6.1M | 0.01% |
1,326,200
-354,300
| -21% | -$1.4M |
|
1580
Nomad Foods
NOMD
$1.64B
| $6.09M | 0.01% |
+431,800
| New | +$5.52M |
|
|
GOL
1581
DELISTED
Gol Linhas Aéreas Inteligentes S.A. American Depositary Shares (Each representing Ten Preferred Shares)
GOL
| $6.09M | 0.01% |
1,340,155
+268,455
| +25% | +$1.48M |
|
|
SUM
1582
DELISTED
Summit Materials, Inc. Class A Common Stock
SUM
| $6.09M | 0.01% |
+217,404
| New | +$5.66M |
|
|
ACH
1583
DELISTED
Alum Corp of China Ltd
ACH
| $6.08M | 0.01% |
472,395
-36,405
| -7% | -$441K |
|
1584
Nice
NICE
$5.99B
| $6.08M | 0.01% |
77,244
-98,700
| -56% | -$7.31M |
|
1585
HNI Corp
HNI
$3.53B
| $6.08M | 0.01% |
152,400
-38,200
| -20% | -$1.67M |
|
1586
Home Bancorp
HBCP
$566M
| $6.07M | 0.01% |
142,700
-7,400
| -5% | -$271K |
|
1587
Ceragon Networks
CRNT
$200M
| $6.06M | 0.01% |
2,377,700
+92,400
| +4% | +$277K |
|
|
INVX
1588
Innovex International
INVX
$2.18B
| $6.02M | 0.01% |
+123,400
| New | +$6.37M |
|
|
WBT
1589
DELISTED
Welbilt, Inc.
WBT
| $6.02M | 0.01% |
319,200
-84,300
| -21% | -$1.65M |
|
1590
FirstCash
FCFS
$9.31B
| $6.01M | 0.01% |
103,124
-132,290
| -56% | -$7.02M |
|
1591
Tompkins Financial
TMP
$1.46B
| $6.01M | 0.01% |
76,300
+3,300
| +5% | +$266K |
|
1592
Workiva
WK
$3.84B
| $6M | 0.01% |
315,200
+248,600
| +373% | +$4.4M |
|
1593
Atlanta Braves Holdings Series B
BATRK
$3.44B
| $6M | 0.01% |
250,400
+145,500
| +139% | +$3.48M |
|
|
CYBE
1594
DELISTED
Cyberoptics Corp
CYBE
| $5.99M | 0.01% |
289,900
-141,700
| -33% | -$3.2M |
|
1595
Stratasys
SSYS
$781M
| $5.98M | 0.01% |
256,596
-221,004
| -46% | -$5.69M |
|
1596
Banco Macro
BMA
$4.96B
| $5.97M | 0.01% |
64,800
+5,000
| +8% | +$440K |
|
1597
Zillow
ZG
$7.91B
| $5.97M | 0.01% |
+122,300
| New | +$5.12M |
|
1598
AppFolio
APPF
$7.23B
| $5.96M | 0.01% |
182,900
+162,390
| +792% | +$4.66M |
|
|
NETI
1599
DELISTED
Eneti Inc.
NETI
| $5.96M | 0.01% |
90,374
-34,816
| -28% | -$2.28M |
|
1600
Lakeland Industries
LAKE
$117M
| $5.96M | 0.01% |
410,924
+17,722
| +5% | +$202K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.